This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


24-26 February 2020|The Westin Miyako Kyoto,Kyoto, Japan


World-renowned scientists sharing the latest technologies, R&D and clinical data to fast-track your next-generation therapeutics towards commercial success

Get a Comprehensive View of the Most Exciting Antibody Science Happening in Asia-Pacific, US, and Europe!

  • Gain New ideas About Discovery, Engineering and Design Strategies to Help You Improve the Properties of Your Antibody Drugs
  • Find Strategies to Overcome the Delivery Challenge and Find New Ways to Cross/Penetrate Biological Barriers with Your Antibody Drug
  • Learn About the Latest Advances and Challenges in Immuno-Oncology Drug Development, Including the Clinical Status of Several New Drugs
  • Hear Case Studies of Antibody-Drug Conjugate (ADC) Development Programs Including Presentations from Daiichi Sankyo, AbbVie Stemcentryx and More
  • Find Out About the Latest Pre-clinical and Clinical Results from Novel Therapeutics and Learn About the Challenges Experienced and Lessons Learned
  • Gain a Competitive Advantage for your New Therapeutic by Learning How to Create Bispecific Antibodies and Multi-Functional Biologics with Better Properties than Existing Therapeutics
New Technologies, R&D Advances and Clinical Data to Help you Fast-Track Next Generation Therapeutics to Market
  • NEW! Workshop on Engineering Strategies for TCR and CAR T Cell Therapies
  • NEW! World-Renowned Academic and Industry Keynotes
  • NEW! Location in Kyoto, Japan
  • EXPANDED! More Confirmed Speakers from Leading US and European Antibody Companies
  • EXPANDED! More Science and Data - 80% of Speakers Are New This Year
  • EXPANDED! Exhibit and Poster Sessions
The Latest Scientific Case Studies and Data from Global Companies at the Forefront of Discovery
  • Invenra, Amgen, Argenx, Xencor, Immatics and AbbVie will present breakthrough case studies and cutting-edge data
  • Eisai will unveil the latest development of Novel Anti-Tau Antibody
  • NBE-Therapeutics will provide an update on  NBE-002, an anthracycline-based immune-stimulatory antibody drug conjugate
  • Sai Reddy will uncover his data on how deep learning enables therapeutic antibody optimization in mammalian cells
  • Genentech will detail MerTK Blockade which enhances anti-tumor immunity
  • Dainippon Sumitomo's Antibody Intracellular Activated Drug Conjugate (AiADC) as a novel ADC technology
Novel Approaches to Accelerate Therapeutic Development To Be Covered
  • Sally Ward’s Research on Targeting Intracellular Trafficking Pathways for the Design of Therapeutics
  • Shohei Koide’s Advances in Novel Therapeutics Based on Synthetic Binding Proteins
  • Lava Therapeutics’ Novel Bispecific γδ-T cell Engagers for the Treatment of Cancer
  • Chugai’s Novel Antibody Engineering to Improve Therapeutic Index of Antibody Targeting Solid Tumors
  • Takeda’s Vision for Antibody Drug Discovery: An Overview of Programs and Progress
  • Koji Tamada’s Prime CAR Technology, a Novel Platform of T cell Therapy Against Solid Tumors


The Westin Miyako Kyoto

1 Awataguchi Kachocho, Higashiyama-ku

Kyoto, 605-0052, Japan

+81 75-771-7111

Get Global Recognition of Your Work by Presenting a Scientific Poster

  1. FOCUSED DISCUSSIONS: Posters offer the opportunity to engage with others also interested in the same subject and application as yourself which could potentially lead to future collaboration. 
  2. RECEIVE IMPARTIAL CRITIQUES: An insightful, impartial discussion of your work by a peer can often provide ideas for improving your work downstream.
  3. HONE YOUR IDEAS: A poster is ideal for early stages of the research, when you may not have much more than an idea, and you stand to benefit a lot from discussing your idea with other researchers from the same field
Deadline to Submit a Poster is 24 January 2020

1 Registration = 2 Events

Your registration to Antibody Engineering & Therapeutics ASIA also accesses AsiaTIDES: Oligonucleotides and Peptide Therapeutics

24-26 February 2020 - The Westin Miyako Kyoto Hotel

Meet the Esteemed Scientific Advisory Board

  • Tomoyuki Igawa, Ph.D., CEO and Research Head, Chugai Pharmabody Research Pte. Ltd., Singapore
  • Qing Li, Ph.D., Scientist I, Medimmune, USA
  • Sai Reddy, Ph.D., Assistant Professor,  ETH Zurich, Switzerland
  • Jijie Gu, Ph.D., Chief Scientific Officer and Executive Vice President,
    WuXi Biologics, China
  • Chengbin Wu, Ph.D., Chief Executive Officer, Shanghai EpimAb Biotherapeutics Inc., China
  • Yong-Sung Kim, Ph.D., Professor, Departments of Molecular Science and Technology, and Applied Chemistry and Biological Engineering, Ajou University, South Korea
  • Karthik Viswanathan, Director, Research, Visterra, Inc., USA
  • Andrew Bradbury, M.D., Ph.D., Chief Scientific Officer, Specifica, USA